Read the News and Earn Credit - Click for Credit

For news and views that matter to pediatricians
Click here »

Optimizing Asthma Diagnosis and Management for Both Physicians and Patients

Bookmark and Share

A CME-Certified Supplement: Earn up to 0.75 CME Credits

Family Practice News



Activity Information

Release Date: November 19, 2014
Expiration Date: November 19, 2015
Estimated time to complete this activity: 45 minutes


Target Audience

This educational activity is designed for physicians who treat patients with asthma.


Educational Needs

Asthma is a chronic, inflammatory airway disease affecting approximately 22 million people in the US, alone. (CDC, 2014) Although asthma sufferers’ quality of life has improved, disease diagnosis and management continue to be suboptimal and thus poses challenges for both clinicians and patients. Exacerbations and improper use of controller medications add to the existing expense of managing a chronic disease. Furthermore, the disease is generally not static in the same individual over time. This necessitates periodic evaluations to adjust treatments and improve patient outcomes. Many practitioners are also lacking in asthma action plan development in conjunction with their patients. This activity will review strategies for assessing and managing asthma and patient education strategies.


Learning Objectives

Upon completion of this activity, participants will be able to:

  • Outline recommendations for the application of spirometry in the diagnosis and assessment of asthma
  • Discuss current and emerging pharmacologic approaches for initiating and adjusting therapy based on asthma severity and level of control
  • Implement patient-centered strategies encompassing individualized treatment approaches and patient expectations
  • Improve patient-clinician communication surrounding asthma symptom control and self-management strategies




Accreditation Statement

Purdue University College of Pharmacy is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Purdue University College of Pharmacy designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Credit

This Enduring Material activity, Optimizing Asthma Diagnosis and Management for Both Physicians and Patients, has been reviewed and is acceptable for up to 0.75 Prescribed credit(s) by the American Academy of Family Physicians. Term of approval begins 11/19/2014. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Supported by educational grants from:

  • Teva Pharmaceuticals
  • Novartis Pharmaceuticals Corporation

Jointly provided by:

How to Claim Credit

To receive credit, participants are required to review the supplement, relate the content material to the learning objectives, achieve at least 66% on the self-assessment, and complete an evaluation form online.

These forms can be completed online at Click on "Use Certificate Code"; Enter the Certificate Code 2949354. A certificate will be immediately available.

Inquiries may be directed to ACHL at (877) 444-8435, ext. 203 or


LeRoy M. Graham, Jr., MD
Associate Clinical Professor of Pediatrics,
Morehouse School of Medicine
Pediatric Pulmonologist,
Georgia Pediatric Pulmonology Associates
Founder, Medical Director,
Not One More Life, Inc.
Atlanta, GA

Faculty Disclosure

Current guidelines require that participants in CME/CE activities be made aware of all affiliations or financial interests that may be perceived as affecting the presentation of the faculty member. Purdue ensures that all faculty and staff involved in the planning, development, and implementation of activities disclose all potential conflicts of interest and resolve them before the CME/CE activity occurs. Complete information will be provided to participants prior to the start of the educational activity.

Purdue University College of Pharmacy requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity. Purdue University College of Pharmacy also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity.

The following financial relationships have been provided:

LeRoy M. Graham, Jr., MD

  • Consulting Agreements/Speakers' Bureau: AstraZeneca, Meda Pharmaceuticals, Inc., and Teva Pharmaceuticals, Inc.
  • Advisory Board Membership: Meda Pharmaceuticals, Inc., and Teva Pharmaceuticals, Inc.
  • Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None

Staff and Reviewer Disclosures

Purdue University College of Pharmacy and ACHL staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.


The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers' prescribing information for these products. Purdue University College of Pharmacy requires the speaker to disclose that a product is not labeled for the use under discussion.

Copyright Statement

This supplement was produced by the Academy for Continued Healthcare Learning.

Neither the editors of Family Practice News, Internal Medicine News, nor the Editorial Advisory Board, nor the reporting staff contributed to its content. The opinions expressed in this supplement are those of the faculty and do not necessarily reflect the views of the supporters, the joint providers, or of the Publisher.

Copyright © 2014 Global Academy for Medical Education LLC and Frontline Medical Communications Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form, by any means, without prior written permission of the Publisher. The Publisher will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

>> Back to Top

click me